Abstract

ObjectiveTo investigate the characteristics of peripheral doses outside electron-beam applicators in Varian TrueBeam linacs. MethodPeripheral doses outside the electron applicator were measured for 6-, 9- and 12-MeV beams at the maximum dose depth (Dmax) for each energy source and at a source-to-surface distance of 100 cm. Measurements were performed using EBT3 films in solid water phantoms. The impact of field size on the penumbra width and peripheral doses was studied using various cutouts, including 3 cm × 3 cm, 6 cm × 6 cm, and 10 cm × 10 cm in a 10 cm × 10 cm applicator with the gantry and collimator at 0°. The influence of the applicator size was investigated using a circular cutout of 5 cm in diameter for various applicator sizes, including 6 cm × 6 cm, 10 cm × 10 cm, 15 cm × 15 cm, 20 × 20 cm, and 25 cm × 25 cm, at Dmax for each energy, while keeping the gantry and collimator angle at 0°. The measured dose profiles were compared with the Eclipse treatment planning system (TPS) predicted dose profiles. The effect of varying gantry angles (0°, 90°, and 270°) for a 3 cm × 3 cm cutout in a 10 cm × 10 cm applicator for each energy source and varying collimator angles (0°, 90°, and 270°) for a 10 cm × 10 cm field were investigated to determine their effects on the penumbra widths and peripheral doses. ResultsBoth the penumbra width and peripheral dose values increased with energy across different field sizes, gantry angles, collimator angles, and applicator sizes. Root Mean Square Deviation (RMSD) analysis indicated minimal differences between the measured profiles and TPS data. Peripheral doses remained below 5% of the maximum dose approximately 10–15 mm away from the field edges, suggesting the potential for implementing additional shielding where required. ConclusionsThis study highlights the importance of considering peripheral doses in electron radiotherapy. It is important to note the impact on healthy tissues beyond the treatment area to ensure patient safety and prevent the long-term side effects of treatment. These findings emphasize the necessity of implementing appropriate measures to minimize peripheral doses.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.